Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
Date:5/9/2013

mpensation expenses, which were allocated to research and development expenses, sales, marketing and distribution expenses, and general and administrative expenses, based on the nature of the work that the relevant employee was assigned to perform, totaled RMB9.8 million (US$1.6 million) for the first quarter of 2013. Share-based compensation expenses for the first quarter of 2012 were RMB3.8 million. The increase was primarily due to restricted shares granted to our management in the second half of 2012.

Income from operations was RMB50.2 million (US$8.1 million) for the first quarter of 2013, representing an increase of 16.0% from RMB43.3 million for the same period in 2012.

Income tax expense for the first quarter of 2013 was RMB6.5 million (US$1.0 million), compared to income tax expense of RMB2.6 million for the same period in 2012. The effective income tax rate increased to 23.9% in the first quarter of 2013 from 10.4% for the same period in 2012. The lower effective income tax rate in the first quarter of 2012 was primarily due to the impact of other operating income of RMB15.6 million in the first quarter of 2012 recorded by our subsidiary located in the British Virgin Islands which is not subject to income tax.

Net income attributable to Simcere was RMB29.9 million (US$4.8 million) for the first quarter of 2013, compared to RMB28.6 million for the same period in 2012. Net margin, representing net income attributable to Simcere divided by total revenue, was 5.7% for the first quarter of 2013, compared to 5.9% for the same period in 2012.

Basic and diluted earnings per American Depository Share ("ADS") for the first quarter of 2013 were RMB0.57 (US$0.09) and RMB0.56 (US$0.09), respectively. One ADS represents two ordinary shares of the Company.

As of March 31, 2013, the Company had cash and pledged bank deposits of RMB332.9 million (US$53.6 million), compared to RMB201.6 mill
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
2. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
3. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
4. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
5. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Legal Counsel
6. Simcere Pharmaceutical Group Announces Receipt of "Going Private" Proposal
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 Results
8. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
9. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
11. Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... -- Releases of the genetically engineered Oxitec ... , , reduced the dengue mosquito population in an ... 95%, well below the modelled threshold for epidemic disease ... The journal PLOS Neglected Tropical Diseases published today the ... The results showed that in Juazeiro city, northeast ...
(Date:7/2/2015)... LAKEWAY, Texas , July 2, 2015   ... on being the leading provider for non-invasive aesthetics in ... offer state-of-the-art tattoo removal treatments with the Astanza Duality ... transform their well being through various medical and laser ... patients with unwanted ink a clear solution to their ...
(Date:7/2/2015)... and DURHAM, N.C. , July 2, ... announced its acquisition of assets related to the ion ... ) that had previously been obtained as part of ... acquired all of Pfizer,s rights to the "Icagen" name ... and will provide comprehensive services for ion channel and ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4
... Bayer HealthCare Pharmaceuticals was handed a pounding $100 ... unlikely to relieve.  The law firm of Sanford Wittels ... U.S. District Court for New Jersey, citing instances of ... employees at Novartis Pharmaceuticals who successfully won a jury ...
... 2011 Beginning April 1, Highmark Blue Cross Blue ... patients with primary immunodeficiency diseases and other rare disorders ... immunoglobulin (IgG - a blood plasma product), regardless of ... even patients who are being treated successfully with another ...
Cached Medicine Technology:Bayer Gets $100M Gender Class Action Headache 2Bayer Gets $100M Gender Class Action Headache 3Bayer Gets $100M Gender Class Action Headache 4Despite New Changes, Highmark Policy Still Threatens Patients With Primary Immunodeficiency Diseases 2Despite New Changes, Highmark Policy Still Threatens Patients With Primary Immunodeficiency Diseases 3
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Renowned ... the dates for the 2016 Dallas Rhinoplasty Symposium . To be held from ... the meeting will be held at the Westin Galleria Dallas. , Designed to take ...
(Date:7/3/2015)... ... , ... Talcum powder attorneys representing clients in national lawsuits announce the launch ... website. Just as the previous version did, the new website will serve as a ... ovarian cancer warning information. The site is routinely updated with news articles on talcum ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Every year, One-to-1 ... Train-a-Thon where they provide members of the Red Deer community with free fitness training ... of fitness training, games, food, events and entertainment raised thousands of charity dollars and ...
(Date:7/2/2015)... ... ... Following the recent report by JAMA Internal Medicine published on June 22, ... emphatically declared a war on obesity in the United States. , "Obesity is one ... the magnitude of this discovery. For that reason, I am declaring, along with my ...
(Date:7/2/2015)... ... ... realized that the gift of poetry was fully in him, as beautiful phrases riddled his ... years later he was publishing an entire book of poetry. He knew there was something ... believed that the best way to lift yourself up, is in the effort of lifting ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2
... Perrigo Company,(Nasdaq: PRGO ; TASE) today announced ... Food and Drug Administration to manufacture and market,Ciclopirox ... The product has been determined to be ... Nail Lacquer, indicated for the,treatment of mild to ...
... Study Data Demonstrated Improved Progression-free Survival with Campath, ... ,Genzyme Corp. (Nasdaq: GENZ ) and Bayer ... that the U.S. Food and Drug Administration,(FDA) has ... (alemtuzumab) and granted regular approval for single-agent,Campath for ...
... Pa., Sept. 21 Cephalon, Inc. (Nasdaq:,CEPH) today ... Application (NDA) to,the U.S. Food and Drug Administration ... treatment of patients with chronic,lymphocytic leukemia (CLL). CLL ... with an estimated 15,000 new cases diagnosed every ...
... grains for breakfast, such as whole-grain barley or rye, ... breakfast, lunch, and dinner. It was previously not known ... This is due to a combination of low GI ... occur in certain grain products. The findings are presented ...
... study by researchers at the University of Southern California suggests ... Researchers found that a storyline on the primetime NBC network ... eating habits had a positive impact on the attitudes and ... in the Sept. 14 Journal of Health Communication and now ...
... Insights might produce treatments to kill off cancer cells, ... New information about a process called unplanned cell death, ... disease, cancer, stroke and other life-threatening conditions, scientists say. ... natural, healthy programmed cell death. Necrosis is an unplanned ...
Cached Medicine News:Health News:Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution 2Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 2Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 3Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 4Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 5Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 6Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4Health News:Right breakfast bread keeps blood sugar in check all day 2Health News:ER episode impacts viewers' health knowledge and behavior 2Health News:Clues to Cell Death Could Fight Disease 2
Bone removing chisel for decortication of lumbar vertebral bodies....
Rasp with down cutting pattern....
9 inch sharp bone hook with grip handle....
Lewin Bone Forceps, serrated and slightly curved. To hold, stabilize, rotate, reduce and,compress bone....
Medicine Products: